Status:
UNKNOWN
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
Lead Sponsor:
Sichuan University
Conditions:
Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC
Eligibility Criteria
Inclusion
- Pathologically confirmed diagnosis of esophageal squamous cell carcinoma
- no preoperative adjuvant therapy
- Karnofsky performance status 0-2;
- The postoperative pathological stage is pT2-4 and / or N + M0 according to AJCC 8th
- Function of the main organs is normal;
- Edition Patient's written informed consent
Exclusion
- Tumor emergencies;
- Abnormal coagulation function;
- Contagious diseases, such as HIV, HBV, HCV infection;
- Mental disorders;
- Concomitant tumors;
- Immunological co-morbidities
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05317325
Start Date
April 1 2022
End Date
April 1 2024
Last Update
April 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610000